To include your compound in the COVID-19 Resource Center, submit it here.

TGR-1202: Phase IIb started

TG Therapeutics began the open-label, U.S. Phase IIb UNITY-DLBCL trial to evaluate oral TGR-1202 daily

Read the full 153 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE